BridgeBio Pharma, Inc. (BBIO) stock soared 9.61% in pre-market trading on Wednesday following the release of its impressive first-quarter 2025 financial results. The biopharmaceutical company significantly outperformed market expectations, particularly with its revenue figures.

The company reported total revenue of $116.63 million for Q1 2025, substantially surpassing the Zacks Consensus Estimate of $61.94 million. A key driver of this revenue beat was the strong performance of Attruby, BridgeBio's treatment for transthyretin amyloid cardiomyopathy (ATTR-CM). Attruby sales reached $36.7 million, far exceeding analyst estimates of $13.10 million. This success indicates a positive market reception for the drug, which received FDA approval in November 2024.

While BridgeBio reported a quarterly adjusted loss of $0.88 per share, it was lower than the expected loss of $0.92 per share and showed improvement from the previous year. The company's strong financial position, with $540.6 million in cash and cash equivalents, further bolstered investor confidence. Additionally, positive clinical data for Attruby, showing a 42% relative risk reduction in cardiovascular hospitalization and mortality at 30 months, has resonated well with healthcare professionals. The market's enthusiastic response to these results reflects growing optimism about BridgeBio's potential in the ATTR-CM market and its robust pipeline, which includes three Phase III readouts expected in the next year.